Publicacións en colaboración con investigadores/as de Hospital Virgen de La Luz de Cuenca (10)

2024

  1. Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 10, pp. 1325-1338

  2. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 5, pp. 604-612

  3. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

2023

  1. Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP

    Journal of Clinical Medicine, Vol. 12, Núm. 14

  2. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  3. Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety

    American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247

  4. Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study

    Alimentary Pharmacology and Therapeutics, Vol. 58, Núm. 1, pp. 60-70

2022

  1. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

2021

  1. Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry

    Journal of Crohn's and Colitis, Vol. 15, Núm. 11, pp. 1846-1851

  2. Tofacitinib in ulcerative colitis: Real-world evidence from the ENEIDA registry

    Journal of Crohn's and Colitis, Vol. 15, Núm. 1, pp. 35-42